Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Clinical trial NCT04960709 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04960709
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-05
- Primary completion
- 2026-03-02
- Enrollment
- 712
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.